Compare Albireo Pharma vs Exelixis
Customers evaluate the quality of Albireo Pharma's products using the following success metrics.
Overview
Albireo Pharma is 16 yrs old and is based in United States.
Albireo Pharma operates as a biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. The company was founded in 2008 and is based in Boston, Massachusetts. In March 2023, Albireo Pharma was acquired by Ipsen. The terms of the transaction were not disclosed.
Exelixis is 30 yrs old and is based in United States.
Exelixis (NASDAQ: EXEL) is a development-stage biotechnology company dedicated to the discovery and development of small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer.
Demo Video
Leadership
Kevin Springman (President)
Stelios B. Papadopoulos (Founder)
Investors
Ipsen, TPG Biotech
Domain Associates, Pappas Ventures
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Albireo Pharma has not claimed their profile.
Work for Albireo Pharma? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Albireo Pharma?
Claim your profile now.
Information not available because Exelixis has not claimed their profile.
Work for Exelixis? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Exelixis?
Claim your profile now.
News & Analysis
Albireo Pharma has been mentioned in our research 1 time.
Exelixis has not been mentioned in our research.
Research Articles
